DiAMS
Financiado
SEMI DISPOSABLE INSULIN PATCH PUMP THE BEST SOLUTION FOR DIABETES PATIENTS
Diabetes is the second more frequent disease in the world with around 422 M cases and about 12% of global health expenditure. Many patients, mostly with type I diabetes, depend on insulin delivery to have a high-quality life and n...
Diabetes is the second more frequent disease in the world with around 422 M cases and about 12% of global health expenditure. Many patients, mostly with type I diabetes, depend on insulin delivery to have a high-quality life and need comfortable, wearable, easy to use and cheap medical devices. In Europe, about 60 M people have diabetes and more than 71 M are estimated by 2040. Around 6 M Europeans have type I diabetes from which about 140.000 are children (the highest world prevalence), making it an European health prority.AMF develops, manufactures and sells microfluidics components for high performance applications. We aim to offering a new solution for insulin treatment for diabetes patients and we have developed a microfluidic technology to serve as a basis for our semi-disposable insulin patch-pump. The use of our intelligent, compact and cost-effective DiAMS will disrupt the field of insulin delivery and make it a safer, more reliable and more mobile for care in hospitals and at home solution. Our system is practically invisible, composed of a patch pump, a continuos glucose monitoring (CGM) and a management interface through a LiNK component that can be controlled through the smartphone. The business opportunities are tremendous because today only Insulet Corporation and Roche offer a product on the patch-pump market, which despite its moderate success have opened the door and let us strongly compete in it thanks to our partially disposable concept and the use if orefilled insulin cartridges. Our technology has many potential applications in drug delivery in the future. DiAMS takes into account the European challenges by making the insulin treatment easier, cheaper, more accurate and more comfortable to patients. In phase 1 we plan to build a detailed feasibility study and business plan to establish the needs for DiAMS commercialization. We estimate a €3.5M funding for phase 2 and potential profits of €59 M after 5 years.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2019-05-06
Fecha Fin: 2019-11-30
Fecha Fin: 2019-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
ADVANCED MICROFLUIDICS SA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.58M€ |
Participante